Alaunos Therapeutics (TCRT) Return on Sales (2011 - 2026)

Alaunos Therapeutics has reported Return on Sales for 14 years, with the latest figure at 13.82% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 836.0% year-over-year to 13.82%; the trailing twelve-month figure through Mar 2026 stood at 13.82% (down 965.0% YoY), and the FY2025 full-year result was 8.45%, down 364.0% from the prior year.
• Return on Sales for Q1 2026 stood at 13.82%, down from 3.02% in the prior quarter.
• The five-year high for Return on Sales was 0.03% in Q3 2022, with the low at 79.49% in Q4 2023.
• Historically, Return on Sales has averaged 12.77% across 5 years, with a median of 6.73% in 2025.
• Annual changes were most pronounced in 2023 — Return on Sales slumped 7094 bps — and 2024, when it soared 7760 bps.
• Alaunos Therapeutics' Return on Sales stood at 8.55% in 2022, then sank by 829 bps to 79.49% in 2023, then soared by 98 bps to 1.89% in 2024, then tumbled by 60 bps to 3.02% in 2025, then plunged by 357 bps to 13.82% in 2026.
• The last three Return on Sales figures came in at 13.82% (Q1 2026), 3.02% (Q4 2025), and 6.79% (Q3 2025), per Business Quant data.